Merck & Co. at CA2
As of the edition of 20 October 2026, Merck & Co. is on route B at CA2 (carbonic anhydrase 2), position 14 of 2,016 on that route, with a score of 0.777.
Sources: ClinicalTrials.gov, approval registers, ChEMBL, FDA Orange Book and Purple Book.
Route and score
Route B Score 0.777
Biology proven in humans0.84
How much the company cares0.83
Room, and a reason to act now0.67
Each part runs from 0 to 1; 0.5 is neutral, and an unknown fact counts as neutral.
What moved the score
Proof in humans at the target+0.294
Took its own drug far in human testing+0.225
Few other companies active at the target+0.128
Active at the target or its disease area recently+0.106
Trials at the target more often meet than miss their main endpoint+0.048
The company’s own follow-on drug+0.044
Why its own drug stopped0.000
The facts that decided the route
- Does the company have its own row at this target, rather than being counted under a drug that acts on many targets? The company has its own row at this target As of 20 October 2026.
- Has the company not been dissolved without a successor? The company still exists or has a successor As of 12 December 2008.
- Does the company have a marketed drug at this target? The company has a marketed drug at this target As of 9 December 1994.
- Does the company have no approved follow-on drug at this target? The company has no approved follow-on of its own As of 9 December 1994.
- Is the protein the drug acts on identified, and not only a complex it belongs to? The protein the drug acts on is on record, not only its complex As of 20 October 2026.
- Does a source say which of the drug's many targets it is designed for? The target the drug is designed for is established As of 20 October 2026.
The drugs
| Drug | Status | Furthest phase | Trials | US protection |
|---|---|---|---|---|
| Dorzolamide | Marketed | Phase 4 | 32 | none listed |
| Dichlorphenamide | Marketed | Phase 3 | 1 | none listed |
The trials behind it
| Trial | Drug | Phase | Status | Years | Participants | Result |
|---|---|---|---|---|---|---|
| NCT00545064 | Dorzolamide | Phase 4 | Completed | 2007 to 2008 | 176 | Mixed result |
| NCT00449956 | Dorzolamide | Phase 3 | Completed | 2007 to 2008 | 474 | Result could not be read |
| NCT00546286 | Dorzolamide | Phase 3 | Completed | 2006 to 2007 | 170 | No results posted |